These results showed that ANC@RNP/crEGFR‐PLK1 treatment can efficiently mediate multiplexed gene editing to decrease glioma growth in vivo, indicating a promising potential for glioma treatment. This evidence concerns the gene PLK1 and central nervous system cancer.